"The 2.5% doesn’t desiccate the intravascular space, but you still get all the benefits of microvascular augmentation," he added.
Dr. Smith noted that DPR with 2.5% Delflex has produced similar results in patients undergoing emergency surgery as well as in those with intestinal obstruction and significant bowel edema. The researchers are currently enrolling adult trauma patients into a prospective randomized trial that will evaluate changes in hepatic blood flow as well as the effect of DPR on the inflammatory process following hemorrhagic shock.
The National Institute of General Medicine Sciences supported this research. Dr. Smith and his coauthors reported no relevant financial disclosures.